Lurbinectedin in small cell lung cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Limited treatment options exist for relapsed small cell lung cancer (SCLC).
• Lurbinectedin, a novel synthetic derivative, targets oncogenic transcription and induces apoptosis.

Purpose of the Study:

• To evaluate the efficacy and safety of lurbinectedin in patients with SCLC progressing after first-line therapy.
• To assess lurbinectedin's role as a second-line treatment for SCLC.

Main Methods:

• Phase II basket trial assessing lurbinectedin (3.2 mg/m²) in pre-treated SCLC patients.
• Phase III trial comparing lurbinectedin plus doxorubicin versus CAV or topotecan.

Main Results:

• Phase II: 35.2% response rate, 3.5 months median progression-free survival (mPFS), 9.3 months median overall survival (mOS).
• Common severe adverse events (grades 3-4) included neutropenia (46%) and leukopenia (29%).
• Phase III: No OS improvement with lurbinectedin combination, but a superior safety profile was observed.

Conclusions:

• Lurbinectedin is approved for second-line SCLC treatment based on Phase II data.
• Ongoing trials investigate lurbinectedin combinations with cytotoxic agents and immune checkpoint inhibitors.
• Further research aims to optimize lurbinectedin's clinical application in SCLC management.